coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF V600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

Paolo A Ascierto; Grant A. McArthur; Brigitte Dréno; James Larkin; Gabriella Liszkay; Michele Maio; Mario Mandala; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Victoria Atkinson; Caroline Dutriaux; Claus Garbe; Ilsung Chang; Stephen P. Hack; Antoni Ribas

首页> 外文期刊>Journal of Translational Medicine >coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF V600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

【24h】

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF V600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

机译：coBRIM：vemurafenib与vemurafenib + cobimetinib在先前未经治疗的BRAF V600突变阳性，无法切除的局部晚期或转移性黑色素瘤患者中进行的三阶段，双盲，安慰剂对照研究（NCT01689519）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Translational Medicine》 |2015年第1期|共页
作者
Paolo A Ascierto; Grant A. McArthur; Brigitte Dréno; James Larkin; Gabriella Liszkay; Michele Maio; Mario Mandala; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Victoria Atkinson; Caroline Dutriaux; Claus Garbe; Ilsung Chang; Stephen P. Hack; Antoni Ribas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
中文文献

1. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial [J] . Gutzmer Ralf, Stroyakovskiy Daniil, Gogas Helen, The Lancet . 2020,第10240期

机译：Atezolizumab，Vemurafenib和Cobimetinib作为无可缩放的先进BRAF（V600）突变阳性黑素瘤（IMSPIRE150）的一线治疗：对随机，双盲，安慰剂控制，第3期试验的主要分析
2. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J] . Ascierto Paolo A., McArthur Grant A., Dreno Brigitte, The lancet oncology . 2016,第9期

机译：Cobimetinib与vemurafenib联合用于晚期BRAF（V600）突变型黑色素瘤（coBRIM）：一项随机，双盲，3期临床试验的最新疗效结果
3. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF(V600) mutation-positive metastatic melanoma treated with vemurafenib +/- cobimetinib [J] . Lewis Karl, Hauschild Axel, Larkin James, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：用vemurafenib +/- cobimetinib处理的BRAF（v600）突变阳性转移性黑素瘤生存伴酸还原剂和vemureafenib剂量的疗效
4. coBRIM: a phase 3 double-blind placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) [O] . Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, 2015

机译：coBRIM：vemurafenib与vemurafenib + cobimetinib在先前未经治疗的BRAFV600突变阳性无法切除的局部晚期或转移性黑色素瘤患者中进行的三阶段双盲安慰剂对照研究（NCT01689519）
5. coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) [O] . Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, 2015

机译：coBRIM：vemurafenib与vemurafenib + cobimetinib在先前未经治疗的BRAFV600突变阳性，无法切除的局部晚期或转移性黑色素瘤患者中进行的三阶段，双盲，安慰剂对照研究（NCT01689519）

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF V600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

著录项

相似文献

相关主题

期刊订阅